menu
    • menu

    Company profile for AlzeCure Pharma

    NEW Drugs in Dev: 6
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in innovative drug research with a primary focus on Alzheimer’s disease. The company is listed on Nasdaq First North Premier Growth Market and is developing five drug candidates based on the two research platforms, NeuroRestore and Alzstatin. The NeuroRestore platform comprises symptom-relieving drug candidates while Alzstatin comprises disease modifying and prev...
    AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in innovative drug research with a primary focus on Alzheimer’s disease. The company is listed on Nasdaq First North Premier Growth Market and is developing five drug candidates based on the two research platforms, NeuroRestore and Alzstatin. The NeuroRestore platform comprises symptom-relieving drug candidates while Alzstatin comprises disease modifying and preventive drug candidates. A diversified portfolio of drug candidates that act on central signaling pathways in the brain also opens up for other indications such as cognitive dysfunctions in traumatic brain injury (TBI).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AlzeCure PharmaSweden Flag
    Country
    Country
    Sweden
    Address
    Address
    Hälsovägen 7, SE-141 57 Huddinge
    Telephone
    Telephone
    559094-8302.
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.alzecurepharma.se/en/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASCO GU

    ASCO GU

    Not Confirmed

    envelop Contact Supplier

    ASCO GU

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    EU Grants Orphan Drug Status to ACD440 Pain Project
    EU Grants Orphan Drug Status to ACD440 Pain Project

    24 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-24/pain-project-acd440-granted-orphan-drug-status-in-the-eu

    PHARMIWEB
    24 Feb 2026
    Share Share
    Alzecure Pharma To Present At Bio-Neuroscience Conference
    Alzecure Pharma To Present At Bio-Neuroscience Conference

    02 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-02/alzecure-pharma-selected-to-present-at-the-bio-neuroscience-conference-in-amsterdam

    PHARMIWEB
    02 Feb 2026
    Share Share
    AlzeCure Secures EU Grant for ACD856 Phase 2 Trial
    AlzeCure Secures EU Grant for ACD856 Phase 2 Trial

    03 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-03/alzecure-receives-payment-of-eu-grant-for-phase-2-clinical-trial-with-neurorestore-acd856-for-alzhei

    PHARMIWEB
    03 Dec 2025
    Share Share
    Alzecure Releases Interim Report Q1-Q3 2025
    Alzecure Releases Interim Report Q1-Q3 2025

    11 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-11/alzecure-publishes-its-interim-report-for-january-september-2025

    PHARMIWEB
    11 Nov 2025
    Share Share
    Response Letter to Previous Article Published about Alzstatin
    Response Letter to Previous Article Published about Alzstatin

    14 Oct 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/response-letter-to-previous-article-published-about-alzstatins-unique-1086663

    ACCESSWIRE
    14 Oct 2025
    Share Share
    Alzecure Pharma To Present At Redeye Neurology Day On October 15
    Alzecure Pharma To Present At Redeye Neurology Day On October 15

    07 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-07/alzecure-pharma-to-present-at-redeye-neurology-day-on-october-15

    PHARMIWEB
    07 Oct 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search